[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
July 2014

Experimental Design Issue for Assessment of Carotenoids Lutein and Zeaxanthin in Age-Related Eye Disease Study 2 Formulation for Age-Related Macular Degeneration

Author Affiliations
  • 1Department of Environment and Primary Industries, Parkville Centre, Parkville, Victoria, Australia
  • 2Department of Epidemiology and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia
JAMA Ophthalmol. 2014;132(7):904. doi:10.1001/jamaophthalmol.2014.1768

To the Editor A recent assessment of the Age-Related Eye Disease Study 2 (AREDS2) trial1,2 of micronutrients for treatment of age-related macular degeneration (AMD) was very interesting, detailed, and insightful.3 One recommendation from the trial was to replace beta carotene in the supplement by the carotenoids lutein and zeaxanthin to minimize risk of lung cancer in smokers and ex-smokers. As observed by Musch,3 this was noteworthy for a clinical trial as it prompted recommendation for reformulation of the original AREDS supplement. A subsequent analysis of subgroups found improved confidence in recommending the replacement and revealed moderate improvements in risk reduction of AMD.2 One important issue deserves further comment and elaboration.